Skip to content

Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients

The Application of Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients - Randomized Controlled Trial

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04409886
Acronym
HBOT
Enrollment
1
Registered
2020-06-01
Start date
2020-06-01
Completion date
2021-01-31
Last updated
2021-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID, Coronavirus

Brief summary

This study is a prospective randomized controlled, double blind clinical trial performed on laboratory confirmed COVID-19 infection admitted patients in the Shamir Medical Center. The trial will include 30 patients who will undergo either hyperbaric oxygen therapy (HBOT) or Normobaric oxygen therapy (NBOT), randomized on a 2:1 ratio, within 4 days in addition to the standard treatment including oxygen, drugs, steroids, bronchodilators, antibiotics and others. The evaluation procedure includes symptom monitoring, room air saturation, vital signs monitoring, pulmonary function and blood tests at baseline, one day and one week after the last session. In addition, one hour prior to and post session saturation and vitals will be monitored.

Detailed description

This study is a prospective randomized controlled, double blind clinical trial performed on laboratory confirmed COVID-19 infection admitted patients at MMC. The trial will include 30 patients who will undergo either HBOT or NBOT, randomized on a 2:1 ratio, within 4 days in addition to the standard treatment including oxygen, drugs, steroids, bronchodilators, antibiotics and others. Sessions will be provided in an MMC monoplace HBO chamber (RestorixHealth). Since all patients demand oxygen supply at room air, the control group is an active arm receiving 100% oxygen. For HBOT, each session will include breathing 100% oxygen at 2.2 absolute atmospheres (ATA) for 60 minutes. Compression and decompression will occur at 1 meter/minute rate. For NBOT, each session will include breathing 100% oxygen at 1.0 absolute atmospheres (ATA) for 60 minutes. In order to blind the patient, the first 5 minutes will include compression for 1.1 ATA and then decompression to 1.0 within the next 5 minutes. During the sessions, the symptoms and vitals will be monitored. The evaluation procedure will include symptom monitoring, room air saturation, vital signs monitoring, pulmonary function and blood tests at baseline, one day and one week after the last session. In addition, one hour prior to and post session saturation and vitals will be monitored. Sessions and evaluations procedures will occur as the following: Protocol Day 1 1. Baseline evaluation: blood test including: arterial blood gases, 2 CBC tubes, 2 Gel tubes (10-15 cc total), vitals (temperature, blood pressure, heart rate, room air saturation), symptoms questionnaire, pulmonary function test. 2. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour prior to session 3. One-hour session NBO/HBO 4. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour after the session. 5. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour before the 2nd session. 6. One-hour session NBO/HBO (8 hours following the first session) 7. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour after the session. 8. Daily oxygen supply dose monitoring. Protocol Day 2-4 1\. Daily symptoms questionnaire 2. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour prior to session One-hour session NBO/HBO 3. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour after the session. 4\. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour before the 2nd session. 5\. One-hour session NBO/HBO (8 hours following the first session) 6. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour after the session. 7\. Daily oxygen supply dose monitoring. Follow up Protocol 1. Repeat evaluations one day after the last session and one week after the last session: * Blood test including: arterial blood gases, 2 CBC tubes, 2 Gel tubes (10-15 cc total) * Vitals (temperature, blood pressure, heart rate, room air saturation) * Symptoms questionnaire * Pulmonary function test. 2. Oropharyngeal swab for SARS-CoV-2 RT-PCR every 3 days for 1 week 3. Clinical monitoring for 30 days

Interventions

BIOLOGICALHyperbaric Oxygen Therapy

Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)

Sponsors

Maimonides Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Within 7 days of patient's need of oxygen supply * Positive SARS-CoV-2 RT-PCR * At least one risk factor for bad prognosis of COVID-19: hypertension, diabetes mellitus, ischemic heart disease, smoking, age\>50, etc. * Respiratory insufficiency: Room Air SpO2 \<94% or PaO2/FiO2\<300mmHg * Age\>18 * Ability to sign an informed consent

Exclusion criteria

* Negative SARS-CoV-2 RT-PCR * HBOT contraindication: pneumothorax, pneumomediastinum, claustrophobia, ear/sinus disease which aren't allowed in HBOT, known chronic pulmonary disease: severe emphysema or known pulmonary bullae. * Pregnancy * Inability to sign an informed consent

Design outcomes

Primary

MeasureTime frameDescription
Oxygenation Indexone day after the last sessionPaO2/FiO2 (Oxygenation Index)

Countries

United States

Participant flow

Participants by arm

ArmCount
HBOT (Hyperbaric Oxygen Therapy)
Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT) Hyperbaric Oxygen Therapy: Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
1
Total1

Baseline characteristics

CharacteristicHBOT (Hyperbaric Oxygen Therapy)
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
1 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
0 Participants
Region of Enrollment
United States
1 Participants
Sex: Female, Male
Female
1 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 1
other
Total, other adverse events
0 / 1
serious
Total, serious adverse events
0 / 1

Outcome results

Primary

Oxygenation Index

PaO2/FiO2 (Oxygenation Index)

Time frame: one day after the last session

Population: PI left institution and the study was terminated with only 1 participant enrolled. No data available to report

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026